<DOC>
	<DOCNO>NCT01536106</DOCNO>
	<brief_summary>The primary objective study determine feasibility safety intracoronary administration autologous bone marrow derive mononuclear cell product patient risk clinically significant cardiac dysfunction follow AMI . The secondary objective study assess effect cardiac function infarct region perfusion . A concurrent placebo control patient group meeting eligibility receive autologous bone marrow derive stem cell evaluate similar treat group ass rate significant spontaneous improvement cardiac function .</brief_summary>
	<brief_title>Rapid Delivery Autologous Bone Marrow Derived Stem Cells Acute Myocardial Infarction Patients .</brief_title>
	<detailed_description>Emerging evidence indicate progenitor stem cell derive bone marrow use improve cardiac function acute myocardial infarction patient . There great potential stem cell therapy , use variety cell precursor contribute new blood vessel formation muscle preservation myocardial infarct zone . The administration cell via infusion infarct relate artery appear feasible result clinical effect study . Across globe AMI lead cause morbidity mortality . This prevent optimal standard therapy i.e . balloon stent dilation infarct vessel . The study double blind , placebo control , randomize , multicenter trial . Male female patient 18-75 year first incidence Acute Myocardial Infarction ( AMI ) LVEF le equal 40 % include study . Patients undergone successful percutaneous intervention ( PCI ) within ≤ 24 hour onset symptom ( PTCA/stent ) / Thrombolysed patient TIMI-3 flow eligible take part study . A total 30 subject recruit randomly assign receive concentrate BMMNC placebo . All patient undergo bone marrow aspiration within 3-10 day index event ( infarction ) . Bone Marrow ( BM ) process utilizing point care technology . Following cell processing , concentrate BMMNC placebo control infuse directly infarct related artery use stop flow method . Clinical follow subject 1,30 , 60 , 90 , 180 360 day perform day procedure , primary secondary end point evaluate study arm .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>Male Female age 18 75 year Incidence first myocardial infarction Acute STEMI LV hypokinesia involve anteroseptal , lateral inferior wall LVEF &lt; 40 % preintervention Successful percutaneous intervention ( PCI ) within ≤ 24 hour onset symptom ( PTCA/stent ) / Thrombolysed patient TIMI3 flow . Written inform consent Multivessel coronary disease require surgical intervention ( CABG ) leave main coronary artery disease &gt; 50 % blockage Previous history CABG Pulmonary edema Cardiogenic shock Myocarditis Renal hepatic dysfunction Hematologic disease General Alcohol drug dependency , active uncontrolled acute myocarditis HIV , HBV , HCV infection Evidence malignant hematological disease Metal implant kind Claustrophobia Renal insufficiency History bleed disorder Anemia ( haemoglobin &lt; 8.5mg/dl ) Platelet count &lt; 100,000/ml</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Cell therapy , Bone marrow stem cell , cardiac cell therapy</keyword>
</DOC>